Merck and Moderna announced positive Phase 3 results for intismeran (individualized neoantigen therapy) combined with pembrolizumab (Keytruda), reporting improved outcomes versus Keytruda alone in the INTerpath-001 trial (NCT05933577). The companies said the regimen outperformed the control on recurrence-free survival (RFS) and also beat Keytruda on distant metastasis-free survival (DMFS). The personalized approach builds an individualized neoantigen vaccine based on each patient’s tumor mutations. The topline results, published in connection with the trial announcement, drew immediate attention from investors focused on next-wave immunotherapy platforms and personalized oncology pipelines. The announcement also sparked market momentum across genomics supply-chain names used in tumor profiling and sequencing, reflecting how mRNA neoantigen therapy can accelerate demand for companion diagnostics and sequencing workflows. For biotech developers, the readout adds another data point to the growing body of evidence that neoantigen-directed mRNA vaccines can translate to clinically meaningful endpoints when paired with checkpoint inhibition.